Vaccine Manufacture and Supply – News and Features

The Company plans to feature its range of regulatory compliant, recombinant and animal-free products and technologies at the annual conference.

Lonza expands its custom service platform to viral vaccines and gene therapy vectors.

A first-of-a-kind, plant-based vaccine factory, takes advantage of plant viral vector technology developed by Fraunhofer CMB for the biopharmaceutical company iBio.

Expansion includes the centralized distribution of the H1N1 flu vaccine to as many as 90,000 sites across the U.S.

Baxter has started full-scale production of a commercial A/H1N1 vaccine using its Vero cell culture technology.

Clinical data from a Phase III and subsequent booster study demonstrate safety, immune response and cross-protective memory.

Novavax, Inc. announced today favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, induced robust neutralizing antibody responses. Novavax's VLP candidate is directed against the H5N1 A/Indonesia/05/2005 avian influenza strain.

Researchers have figured out a way to genetically disarm the virus and making the agent safe to study under conditions far less stringent than those currently imposed.

The £1million facility will produce clinical trial material manufactured to the approved quality.